הכנסות שנתיות של החברה Opus Genetics, Inc. (IRD)
Opus Genetics Inc (IRD) automates the development of drugs for rare eye pathologies via robotic platforms. The company aims to prevent blindness by utilizing AAV vectors for the delivery of healthy genes. The company's gross sales volume trend shows that the current mark is 0.01. The startup is currently focusing on primary clinical trials of its portfolio before attracting major international partners.
פילוחי מדדים מקיפים ואנליטיקה עבור Opus Genetics, Inc. (IRD)
This indicator captures actual daily cash inflows, excluding accounting adjustments to assess real demand. At Opus Genetics Inc (IRD), such liquidity is critically dependent on external financing to offset colossal R&D expenditures for rare eye disease therapies. Analyzing the company's sales metrics allows for the timely detection of operational capital deficits. The stability of this line confirms the business's financial resilience in the face of clinical trial risks.
